Need an investment idea? Check out Popular Stocks and S2O Stock Screener.

Market Price

44.73 

-0.17 -0.4%

as of May 24 '19

52 Week Range:

27.30 46.19


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, and markets pharmaceutical products worldwide. The company offers prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone compilations; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine and donepezil for treating Alzheimer's disease; laninamivir for anti-influenza treatment; and silodosin for treating dysuria. It also provides olmesartan and Telmisartan antihypertensive agents; levofloxacin, an antibacterial agent; pravastatin and Rosuvastatin antihyperlipidemic agents; iohexol to enhance the visibility of diagnostic X-ray imaging; loxoprofen, an anti-inflammatory analgesic; and naloxegol for opioid-induced constipation treatment. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a cold remedy; Loxonin S, an anti-inflammatory analgesic; Transino for treating melisma/alleviating spots, freckles, and pigmentation; Minon, a moisturizing cleanser; and Clean Dental, an oral care product. Additionally, the company offers Influenza HA Vaccine; Rotarix Oral Liquid, a vaccine for prevention of rotavirus; ActHIB, a haemophilus influenzae type b vaccine; Live Attenuated Measles-Rubella Combined Vaccine; and Squarekids, a vaccine for the prevention of pertussis, diphtheria, tetanus, and poliomyelitis. It also offers pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration agreements with Roche for the development of a HER2 diagnostic test; Sarah Cannon Research Institute to develop novel cancer therapies; and Integral Molecular, Inc. The company was founded in 1899 and is headquartered in Tokyo, Japan.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Mar '09 Mar '10 Mar '11 Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19
Equity (BVPS) 9.51
9.79
10.31
10.26
9.82
9.69
12.10
14.86
15.47
14.10
growth rate 2.9% 5.3% -0.5% -4.3% -1.3% 24.9% 22.8% 4.1% -8.9%
Earnings BIT 111,553.00
74,424.00
130,413.00
88,929.00
76,283.00
129,006.00
growth rate -33.3% 75.2% -31.8% -14.2% 69.1%
Avg.PE 27.13
27.19
54.99
44.07
growth rate 0.2% 102.2% -19.9%
ROA -14.45
2.81
4.72
0.69
4.21
3.48
16.79
4.24
2.80
3.16
growth rate 100.0% 68.0% -85.4% 510.1% -17.3% 382.5% -74.8% -34.0% 12.9%
ROE -20.43
4.85
8.19
1.25
7.86
7.48
24.70
6.49
4.44
5.22
growth rate 100.0% 68.9% -84.7% 528.8% -4.8% 230.2% -73.7% -31.6% 17.6%
ROIC -17.96
3.69
6.18
0.99
5.93
5.28
19.81
5.56
3.73
4.17
growth rate 100.0% 67.5% -84.0% 499.0% -11.0% 275.2% -71.9% -32.9% 11.8%
Cur. Ratio 1.54
3.05
2.91
2.18
2.16
2.15
2.64
2.96
3.67
3.40
growth rate 98.1% -4.6% -25.1% -0.9% -0.5% 22.8% 12.1% 24.0% -7.4%
Quick Ratio 0.99
2.04
2.04
1.39
1.40
1.68
2.08
2.54
3.15
2.88
growth rate 106.1% 0.0% -31.9% 0.7% 20.0% 23.8% 22.1% 24.0% -8.6%
Leverage 1.73
1.73
1.74
1.88
1.85
1.88
1.52
1.54
1.63
1.68
growth rate 0.0% 0.6% 8.1% -1.6% 1.6% -19.2% 1.3% 5.8% 3.1%
Balance Sheet Mar '09 Mar '10 Mar '11 Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19
Acct.Receivable 235,809.00
269,194.00
241,547.00
248,762.00
231,867.00
231,529.00
419,609.00
growth rate 14.2% -10.3% 3.0% -6.8% -0.2% 81.2%
Acct.Payable 59,798.00
245,422.00
235,546.00
241,831.00
219,759.00
226,164.00
312,660.00
growth rate 310.4% -4.0% 2.7% -9.1% 2.9% 38.2%
Cur.Assets 943,643.00
990,603.00
785,334.00
1,125,268.00
1,197,788.00
1,201,545.00
1,393,184.00
growth rate 5.0% -20.7% 43.3% 6.4% 0.3% 16.0%
Total Assets 1,644,071.00
1,854,037.00
1,982,286.00
1,900,522.00
1,914,979.00
1,897,754.00
2,088,051.00
growth rate 12.8% 6.9% -4.1% 0.8% -0.9% 10.0%
Cash 160,956.00
183,070.00
189,372.00
222,159.00
246,050.00
357,702.00
243,155.00
growth rate 13.7% 3.4% 17.3% 10.8% 45.4% -32.0%
Inventory 174,430.00
189,408.00
150,093.00
144,273.00
153,138.00
172,586.00
176,067.00
growth rate 8.6% -20.8% -3.9% 6.1% 12.7% 2.0%
Cur.Liabilities 436,111.00
461,188.00
297,070.00
379,694.00
325,759.00
353,105.00
384,544.00
growth rate 5.8% -35.6% 27.8% -14.2% 8.4% 8.9%
Liabilities 728,327.00
846,510.00
675,245.00
667,001.00
743,551.00
764,714.00
838,347.00
growth rate 16.2% -20.2% -1.2% 11.5% 2.9% 9.6%
LT Debt 200,917.00
263,289.00
201,000.00
181,000.00
280,543.00
260,564.00
220,585.00
growth rate 31.0% -23.7% -10.0% 55.0% -7.1% -15.3%
Equity 979,933.00
1,304,057.00
1,231,406.00
1,175,897.00
1,132,982.00
1,249,642.00
growth rate 33.1% -5.6% -4.5% -3.7% 10.3%
Common Shares 708.00
704.00
705.00
705.00
705.00
705.00
705.00
691.00
673.00
662.00
50,000.00
growth rate -0.6% 0.1% 0.0% 0.0% 0.0% 0.0% -2.0% -2.6% -1.6% 7,452.9%
Cash Flow Statement Mar '09 Mar '10 Mar '11 Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19
Capital Expenditures 73,173.00
47,497.00
38,500.00
27,136.00
24,766.00
23,399.00
36,108.00
growth rate -35.1% -18.9% -29.5% -8.7% -5.5% 54.3%
Cash Dividends 42,238.00
42,254.00
48,468.00
43,889.00
46,420.00
45,339.00
growth rate 0.0% 14.7% -9.5% 5.8% -2.3%
Cash From OA 129,247.00
37,304.00
142,776.00
174,281.00
136,234.00
108,439.00
92,033.00
growth rate -71.1% 282.7% 22.1% -21.8% -20.4% -15.1%
FCF per Share 0.36
1.13
1.27
0.85
0.26
-0.13
0.72
0.49
1.32
0.67
growth rate 213.9% 12.4% -33.1% -69.4% -100.0% 100.0% -31.9% 169.4% -49.2%
Sale Purchase of Stock 1.00
1.00
1.00
1.00
1.00
growth rate 0.0% 0.0% 0.0% 0.0%
FCF 33,781.00
99,078.00
105,007.00
28,869.00
50,385.00
-17,210.00
48,146.00
97,860.00
83,272.00
70,431.00
55,925.00
growth rate 193.3% 6.0% -72.5% 74.5% -100.0% 100.0% 103.3% -14.9% -15.4% -20.6%
Income Statement Mar '09 Mar '10 Mar '11 Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19
Sales 997,852.00
1,118,241.00
919,372.00
986,446.00
955,124.00
960,195.00
929,717.00
growth rate 12.1% -17.8% 7.3% -3.2% 0.5% -3.2%
Op.Income 68,194.00
111,553.00
74,424.00
130,413.00
88,929.00
76,283.00
129,006.00
growth rate 63.6% -33.3% 75.2% -31.8% -14.2% 69.1%
IBT 99,775.00
79,937.00
122,387.00
87,788.00
81,021.00
85,830.00
growth rate -19.9% 53.1% -28.3% -7.7% 5.9%
Net Income 68,194.00
60,943.00
322,119.00
82,282.00
53,466.00
60,282.00
93,409.00
growth rate -10.6% 428.6% -74.5% -35.0% 12.8% 55.0%
EPS -304.22
59.42
99.52
14.73
90.81
86.41
456.62
119.11
79.44
91.10
growth rate 100.0% 67.5% -85.2% 516.5% -4.9% 428.4% -73.9% -33.3% 14.7%
Gross Profit 684,195.00
715,952.00
596,285.00
667,824.00
605,751.00
614,174.00
580,212.00
growth rate 4.6% -16.7% 12.0% -9.3% 1.4% -5.5%
R&D 191,212.00
190,666.00
208,656.00
214,347.00
236,046.00
173,511.00
growth rate -0.3% 9.4% 2.7% 10.1% -26.5%

Quarterly Statements

Item Name Mar '18 Jun '18 Sep '18 Dec '18 Mar '19
Earnings BIT -16,943.00
29,918.00
28,067.00
39,099.00
31,923.00
growth rate 100.0% -6.2% 39.3% -18.4%
Balance Sheet Mar '18 Jun '18 Sep '18 Dec '18 Mar '19
Acct.Receivable 231,529.00
230,113.00
270,773.00
305,741.00
419,609.00
growth rate -0.6% 17.7% 12.9% 37.2%
Acct.Payable 226,164.00
221,857.00
256,656.00
260,204.00
312,660.00
growth rate -1.9% 15.7% 1.4% 20.2%
Cur.Assets 1,201,545.00
1,177,032.00
1,220,385.00
1,225,926.00
1,393,184.00
growth rate -2.0% 3.7% 0.5% 13.6%
Total Assets 1,897,754.00
1,891,394.00
1,907,941.00
1,893,589.00
2,088,051.00
growth rate -0.3% 0.9% -0.8% 10.3%
Cash 357,702.00
293,983.00
236,852.00
239,167.00
243,155.00
growth rate -17.8% -19.4% 1.0% 1.7%
Inventory 172,586.00
184,094.00
186,591.00
177,573.00
176,067.00
growth rate 6.7% 1.4% -4.8% -0.9%
Cur.Liabilities 353,105.00
306,254.00
321,801.00
330,703.00
384,544.00
growth rate -13.3% 5.1% 2.8% 16.3%
Liabilities 764,714.00
679,814.00
659,942.00
658,571.00
838,347.00
growth rate -11.1% -2.9% -0.2% 27.3%
LT Debt 260,564.00
220,569.00
220,575.00
220,580.00
220,585.00
growth rate -15.4% 0.0% 0.0% 0.0%
Equity 1,132,982.00
1,211,527.00
1,247,943.00
1,234,953.00
1,249,642.00
growth rate 6.9% 3.0% -1.0% 1.2%
Common Shares 50,000.00
50,000.00
50,000.00
50,000.00
50,000.00
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Mar '18 Jun '18 Sep '18 Dec '18 Mar '19
Capital Expenditures 7,327.00
7,481.00
7,279.00
6,781.00
14,567.00
growth rate 2.1% -2.7% -6.8% 114.8%
Cash Dividends 22,682.00
22,682.00
22,715.00
22,715.00
growth rate 0.0% 0.2% 0.0%
Cash From OA 64,590.00
-11,817.00
18,466.00
14,045.00
71,339.00
growth rate -100.0% 100.0% -23.9% 407.9%
Sale Purchase of Stock
growth rate
FCF 57,263.00
-19,298.00
11,187.00
7,264.00
56,772.00
growth rate -100.0% 100.0% -35.1% 681.6%
Income Statement Mar '18 Jun '18 Sep '18 Dec '18 Mar '19
Sales 219,148.00
225,737.00
221,112.00
256,229.00
226,637.00
growth rate 3.0% -2.1% 15.9% -11.6%
Op.Income -16,943.00
29,918.00
28,067.00
39,099.00
31,923.00
growth rate 100.0% -6.2% 39.3% -18.4%
IBT -16,713.00
29,629.00
29,005.00
39,320.00
-12,126.00
growth rate 100.0% -2.1% 35.6% -100.0%
Net Income -12,320.00
23,951.00
20,063.00
34,784.00
14,610.00
growth rate 100.0% -16.2% 73.4% -58.0%
Gross Profit 128,577.00
140,989.00
139,214.00
157,974.00
142,034.00
growth rate 9.7% -1.3% 13.5% -10.1%
R&D 60,418.00
45,460.00
48,197.00
48,924.00
30,929.00
growth rate -24.8% 6.0% 1.5% -36.8%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

F (2.17)

YOY Growth Grade:

F (7.07)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 45.16 46.02
EPS / Growth 0.97

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 3.6%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 3.6% 3.6% 3.6%
Future PE 0.01 3.57 3.57
Future EPS 1.38 1.38 1.38
Value Price
MOS %
0.00
-100.0%
1.22
-97.3%
1.22
-97.3%
MOS Price 0.00 0.61 0.61
IRT 27.11 27.11 27.11

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.